title: The FDA reboot of antibiotic development.
authors.affiliation: Anti-infectives Consulting, LLC, Stonington, Connecticut, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Shlaes
authors.forename: Dan
authors.initials: D
authors.lastname: Sahm
authors.forename: Carol
authors.initials: C
authors.lastname: Opiela
authors.forename: Brad
authors.initials: B
authors.lastname: Spellberg
mesh_terms: D000900:Anti-Bacterial Agents; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000900:Anti-Bacterial Agents
references.citation: Clin Infect Dis. 2011 Dec;53(12):1308-9; author reply 1309-10
references.pmid: 22028435
references.citation: Nature. 2011 Apr 7;472(7341):32
references.pmid: 21475175
references.citation: Lancet Infect Dis. 2008 Feb;8(2):83-5
references.pmid: 18222155
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Mar 8;62(9):165-70
references.pmid: 23466435
references.citation: Clin Microbiol Infect. 2004 Nov;10 Suppl 4:18-22
references.pmid: 15522036
references.citation: N Engl J Med. 2013 Jan 24;368(4):299-302
references.pmid: 23343059
references.citation: Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011
references.pmid: 18947320
references.citation: Lancet Infect Dis. 2013 Mar;13(3):269-75
references.pmid: 23332713
references.citation: Nat Rev Drug Discov. 2012 Feb 01;11(2):168
references.pmid: 22293569
references.citation: Expert Rev Anti Infect Ther. 2012 Nov;10(11):1311-9
references.pmid: 23241188
references.citation: Clin Infect Dis. 2012 Oct;55(8):1031-46
references.pmid: 22891041
references.citation: Clin Infect Dis. 2002 Feb 1;34(3):420-2
references.pmid: 11774094
references.citation: Ann Intern Med. 2000 Sep 19;133(6):455-63
references.pmid: 10975964
references.citation: Br Med J. 1937 Jul 17;2(3993):101-4
references.pmid: 20780782
references.citation: Br Med J. 1937 Dec 11;2(4014):1156-9
references.pmid: 20781102